Patient data obtained from a cancer genome map show (27) that TP53-MT is a potential indicator of relatively good response of bladder cancer patients to ICIs, and is related to prolonged overall survival (OS) [HR = 0.65 (95% CI 0.44-0.99), p = 0.041]. Here, TP53 is linked to cancer.